Clinical Trials Available
To view a list of available clinical trials, select a type of cancer below. You will get a general overview of the trial, the trial number, and a link to clinicaltrials.gov for the most complete information.
Our collaboration with Sarah Cannon Research Institute (SCRI), one of the world’s leading oncology research organizations conducting community-based clinical trials, offers our patients early access to the latest in leading-edge treatments without having to leave the Twin Cities region.
Request Clinical Trial Information
SOLID TUMOR:
23253 / NCT05868629: Dabrafenib Plus Trametinib In Patients With BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors. Excludes NSCLC, melanoma, anaplastic thyroid, biliary, glioma, and CRC.
Learn more: https://clinicaltrials.gov/study/NCT05868629
23328 / NCT06581432: A Phase II study of oral zongertinib (BI 1810631) for the treatment of previously treated HER2-mutated or overexpressed/amplified solid tumors. Must have not received a HER2 TKI.
Learn more: https://clinicaltrials.gov/study/NCT06581432
BREAST CANCER:
HR+/HER2-
Adjuvant
22332 / NCT05827081: Adjuvant-WIDER. Phase IIIb study of Ribociclib plus endocrine therapy in high-risk early breast cancer within 3 years of surgery.
Learn more: https://clinicaltrials.gov/study/NCT05827081
1L metastatic
23251 / NCT06380751: Phase 3 study of Saruparib (AZD5305) + Camizestrant vs CDK4/6 Inhibitor + ET or Camizestrant for 1st line treatment of BRCA1, BRCA2, or PALB2-mut Pts with hormone receptor positive, HER2 negative advanced or metastatic breast cancer
Learn more: https://clinicaltrials.gov/study/NCT06380751
2L+ metastatic
23107 / NCT06016738: OPERA-01. Phase 3 study of OP-1250 vs standard of care for ER+, HER2- advanced or MBC following ET & CDK4/6 inhibitor
Learn more: https://clinicaltrials.gov/study/NCT06016738
25042 / NCT06982521: RLY-2608 + Fulvestrant vs. Capivasertib + Fulvestrant for PIK3CA-mutant HR+/HER2- locally advanced or metastatic breast cancer following recurrence or progression with CDK4/6 Inhibitor. Prior PI3K treatment excluded.
Learn more: https://clinicaltrials.gov/study/NCT06982521
HER2+
Adjuvant
21462 / NCT05232916: FLAMINGO 01: Phase 3 study of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2+patients with residual disease or High-Risk PCR after both neoadjuvant and adjuvant trastuzumab-based treatment. Only offered at Maple Grove
Learn more: https://clinicaltrials.gov/study/NCT05232916
TRIPLE-NEGATIVE
Adjuvant
22258 / NCT05633654: ASCENT-05: Phase 3 study of Adjuvant Sacituzumab Govitecan & Pembro vs physician’s choice in TNBC with residual disease after surgery and neoadjuvant therapy. BRCA excluded.
Learn more: https://clinicaltrials.gov/study/NCT05633654
1L locally advanced / Metastatic
24325 / NCT06926868: IZABRIGHT-BREAST01: Phase 2/3 study evaluating Izalonamab brengitecan vs treatment of physician’s choice in patients with previously untreated locally advanced or metastatic triple negative breast cancer OR ER-low HER2 neg MBC ineligible for anti-PD(L)1 therapy.
Learn more: https://clinicaltrials.gov/study/NCT06926868
22320 / NCT06103864: Phase III study of Datopotamab Deruxtecan (Dato-DXd) w/wo Durvalumab vs investigator’s choice in combination with Pembrolizumab in pts with PD-L1 positive locally recurrent inoperable or metastatic triple negative breast cancer
Learn more: https://clinicaltrials.gov/study/NCT06103864
BILIARY
2L+ Metastatic
23066 / NCT05727176: A phase 2 study of Futibatinib for advanced cholangiocarcinoma with FGFR2 fusions or rearrangements. Must have received at least one line of Gem/platinum based therapy.
Learn more: https://clinicaltrials.gov/study/NCT05727176
23328 / NCT06581432: A Phase II study of oral zongertinib (BI 1810631) for the treatment of previously treated HER2 overexpressed / amplified solid biliary tumors
Learn more: https://clinicaltrials.gov/study/NCT06581432
23165 / NCT05948475: A phase 3 study of oral Tinengotinib versus physician’s choice in FGFR-altered locally advanced / metastatic CCA who have received at least one line of chemotherapy and one line of FGFR inhibitor therapy
Learn more: https://clinicaltrials.gov/study/NCT05948475
PANCREATIC
2L+ Locally advanced / Metastatic
23292 / NCT04657068: A Phase I/IIa study of ATR Kinase Inhibitor ART0380 with irinotecan in patients with ATM ultra-low metastatic or locally advanced PDAC or acinar cell carcinoma as 2nd line. Prior irinotecan allowed. Okay to screen prior to progression.
Learn more: https://clinicaltrials.gov/study/NCT04657068
GASTRIC
1L Locally advanced / Metastatic
24152 / NCT06764875: Phase 3 study of Rilvegostomig with Fluoropyramidine and T-DXd versus chemo, Trastuzumab, and Pembrolizumab for 1st line in Her2+ locally advanced or metastatic cancer
Learn more: https://clinicaltrials.gov/study/NCT06764875
COLON/RECTAL
Adjuvant
24328 / NCT07023289: Phase 2 study of Telisotuzumab Adizutecan vs standard of care in patients with post adjuvant ctDNA Positive CRC and NED on imaging. MSI-H/dMMR excluded
Learn more: https://clinicaltrials.gov/study/NCT07023289
1L Metastatic
25154 / NCT07221357: A blinded randomized phase 2/3 study of Pumitamig with chemotherapy vs Bevacizumab with chemo in patients with previously untreated metastatic CRC. MSI/H/dMMR, BRAF V600E or prior immunotherapy excluded.
Learn more: https://clinicaltrials.gov/study/NCT07221357
2L+ Metastatic
24246 / NCT07011576: Phase 2 study of Fruquintinib + FOLFIRI as 2nd line for metastatic CRC. Must have received FOLFOX and Bevacizumab as 1st line.
Learn more: https://clinicaltrials.gov/study/NCT07011576
23292 / NCT04657068: A Phase I/IIa study of ATR Kinase Inhibitor ART0380 with irinotecan in patients with ATM negative metastatic CRC as 3rd line. Must have had 5-FU, oxali, and irinotecan previously. Okay to screen prior to progression.
Learn more: https://clinicaltrials.gov/study/NCT04657068
23328 / NCT06581432: A Phase II study of oral zongertinib (BI 1810631) for the treatment of previously treated HER2 overexpressed / amplified CRC and have not received a HER2 TKI.
Learn more: https://clinicaltrials.gov/study/NCT06581432
NON-SMALL CELL LUNG CANCER
23329: Increasing biomarker testing rates in pt with early stage, locally advanced, or metastatic NSCLC who are initiating 1st line tx for a new/recurrent dx.
Adjuvant
24320 / NCT07154706: TRUST-IV: Phase 3 study of adjuvant Talectrectinib versus placebo in patients with ROS1-fusion positive stage IB-IIIA NSCLC who have undergone complete tumor resection.
Learn more: https://clinicaltrials.gov/study/NCT07154706
1L Unresectable or Metastatic
25156 Accelero / NCT07222566: Phase 3, double-blind, randomized study of PF-08634404 in combination with chemotherapy vs. pembrolizumab in combination with chemotherapy in locally advanced or metastatic NSCLC. Squamous or non-squamous eligible. EGFR, ALK, and ROS1 mutant excluded.
Learn more: https://clinicaltrials.gov/study/NCT07222566
24232 / NCT06765109 ALKAZAR: Phase 3 study of selective ALK inhibitor NVL-655 compared to Alectinib for 1st line treatment in patients with ALK+ advanced NSCLC
Learn more: https://clinicaltrials.gov/study/NCT06765109
24305 / NCT07185997 ALPACCA: Phase 3 study of Firmonertinib vs Osimertinib or Afatinib as 1st line therapy for locally advanced / metastatic NSCLC with EGFR PACC or less common EGFR mutations
Learn more: https://clinicaltrials.gov/study/NCT07185997
20270 / NCT04613596 Krystal-7: Phase 3 study of Adagrasib monotherapy and in combination with Pembrolizumab in advanced NSCLC with KRAS G12C Mutation. Must be PD-L1 >/= 50%.
Learn more: https://clinicaltrials.gov/study/NCT04613596
2L+ Metastatic:
25091 / NCT07144280: Phase 3, open-label study of PF-080046054/SGN-PDL1V vs Docetaxel in previously treated PD-L1 positive NSCLC. ALK and EGFR included
Learn more: https://clinicaltrials.gov/study/NCT07144280
22067 / NCT05579366: Phase 1/2 Study of Rinatabart sesutecan (Rina-S) in pts with EGFR mutated NSCLC. Must have received EGFR targeted therapy and platinum-based chemotherapy
Learn more: https://clinicaltrials.gov/study/NCT05579366
24264 / NCT05267626: AU-007: Phase 1/2 study of AUC-007, a monoclonal antibody that binds to IL2 and inhibits IL-2R binding for PDL1+ NSCLC that has progressed on prior PD-L1 therapy
Learn more: https://clinicaltrials.gov/study/NCT05267626
23328 / NCT06581432: A Phase II study of oral zongertinib (BI 1810631) for the treatment of previously treated HER2 overexpressed/ amplified non-squamous NSCLC. HER2 mutant NSCLC and previously HER2 TKI are excluded.
Learn more: https://clinicaltrials.gov/study/NCT06581432
SMALL CELL LUNG CANCER
Limited Stage:
24312 / NCT06773910: BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab as consolidation therapy following chemo/rad in limited-stage SCLC
Learn more: https://clinicaltrials.gov/study/NCT06773910
2-3L Metastatic:
23243 / NCT06095505: Alisertib PO in patients with extensive stage small cell lung cancer in 2-3 line.
Learn more: https://clinicaltrials.gov/study/NCT06095505
PROSTATE
24310 / NCT05413421: 1L Phase 1/1b study of ORIC-944 alone or in combination with androgen receptor pathway inhibitor in patients with metastatic prostate cancer. Only available at Maple Grove
Learn more: https://clinicaltrials.gov/study/NCT05413421
RENAL CELL CARCINOMA
25176 / NCT07227415: Phase 1b/2 study of Pf-08634404 (PD-1/VEGF bispecific antibody) monotherapy and in combination with other anticancer agents in first line locally advanced or metastatic renal cell carcinoma.
Learn more: https://clinicaltrials.gov/study/NCT07227415
HEAD AND NECK
1L Recurrent or Metastatic
24170 / NCT06788990: FORTIFI-HN01: Phase 2/3 trial investigating ficerafusp alfa + pembrolizumab vs placebo + pembrolizumab for 1st line pts with recurrent or metastatic PDL+ HNSCC in oral cavity, hypopharynx, larynx or oropharynx (OPSCC must be HPV negative).
Learn more: https://clinicaltrials.gov/study/NCT06788990
2L + Metastatic
24004 /NCT06496178: A phase 3 study of Petosemtamab compared with investigator’s choice monotherapy in previously treated incurable, metastatic/ recurrent head and neck SCC. Eligible primary tumor sites OP, OC, HP, LX.
Learn more: https://clinicaltrials.gov/study/NCT06496178
23328 / NCT06581432: A Phase II study of oral zongertinib (BI 1810631) for the tx of previously treated HER2 overexpressed/ amplified salivary gland cancers.
Learn more: https://clinicaltrials.gov/study/NCT06581432
MELANOMA / cSCC
Locally advanced or Metastatic
23335 / NCT06246916: Phase 3 study of Fianlimab & Cemiplimab versus Relatlimab & Nivolumab in unresectable or metastatic melanoma for 1st line treatment
Learn more: https://clinicaltrials.gov/study/NCT06246916
24217 / NCT05479812: Phase I/Ib study of WTX-124 monotherapy and in combination with pembro for melanoma and cutaneous SCC. Only available at Maple Grove.
Learn more: https://clinicaltrials.gov/study/NCT05479812
24264 / NCT05267626: Phase 1/2 study of AU-007, a monoclonal antibody that binds to IL2 and inhibits IL-2R binding for melanoma that has progressed during or following PD-L1 therapy.
Learn more: https://clinicaltrials.gov/study/NCT05267626
HEMATOLOGY
CLL
22331 / NCT05963074 TAILOR: A study to customize Ibrutinib treatment regimens in previously untreated CLL.
Learn more: https://clinicaltrials.gov/study/NCT05963074
DLBCL
24205 / NCT06890884: 1st line phase 2 study comparing Zilovertamab Vedotin in combination with R-CHP vs Polatuzumab Vedotin with R-CHP in treatment naïve patients with GCB subtype DLBCL.
Learn more: https://clinicaltrials.gov/study/NCT06890884
MULTIPLE MYELOMA
24145 / NCT05519085: Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) versus Pomalidomide, Bortezomib and Dex (PVd) in RRMM
Learn more: https://clinicaltrials.gov/study/NCT05519085
GYNECOLOGY
CERVICAL
21365 / NCT04831580: ROCC: Robotic versus Open Radical Hysterectomy for early stage cervical cancer
Learn more: https://clinicaltrials.gov/study/NCT04831580
FALLOPIAN TUBE
21270 / NCT05128825: A Phase 2 study to evaluate efficacy and safety of ZN-c3 in fallopian tube cancer in the 2+ line
Learn more: https://clinicaltrials.gov/study/NCT05128825
24112 CATALINA-2 / NCT06690775: Phase 2 study of TORL-1-23 in advanced platinum resistant epithelial fallopian tube cancers expressing claudin 6 in 2-4 line setting. Tumor must be CLDN6+ positive
Learn more: https://clinicaltrials.gov/study/NCT06690775
25114 MAESTRA 1 / NCT07023627: Phase 2 study of INCB123667 as 2-5L treatment in patients with platinum resistant high grade serous epithelial OC, FP, or PPC with Cyclin E1 overexpression.
Learn more: https://clinicaltrials.gov/study/NCT07023627
ENDOMETRIAL
24306 / NCT06952504: Phase 3 study of Sacituzumab Tirumotecan in combination with pembrolizumab vs pembrolizumab Alone as 1st line maintenance treatment in patients with MMR proficient disease
Learn more: https://clinicaltrials.gov/study/NCT06952504
24100 / NCT06463028: Phase 2 study of Sapanisertib and Serabelisib (PIKTOR) with Paclitaxel for 2nd line or later advanced or recurrent endometrial cancer. PI3K/AKT/mTOR pathway gene alteration required. Optional substudy with insulin suppressing diet.
Learn more: https://clinicaltrials.gov/study/NCT06463028
22037 PYNNACLE / NCT04585750: Phase 1/2 study of PC14586 in patients with locally advanced or metastatic solid tumors with TP53 Y220C mutation
Learn more: https://clinicaltrials.gov/study/NCT04585750
OVARIAN
24112 CATALINA-2 / NCT06690775: Phase 2 study of TORL-1-23 in advanced platinum resistant epithelial ovarian (including primary peritoneal and fallopian tube cancers) expressing claudin 6 in 2-4 line setting. Tumor must be CLDN6+ positive
Learn more: https://clinicaltrials.gov/study/NCT06690775
23289 / NCT06072781: Avutometinib plus Defactinib Versus SOC in Patients with recurrent low-grade serous ovarian cancer
Learn more: https://clinicaltrials.gov/study/NCT06072781
22037 PYNNACLE / NCT04585750: Phase 1/2 study of PC14586 in patients with locally advanced or metastatic solid tumors with TP53 Y220C mutation
Learn more: https://clinicaltrials.gov/study/NCT04585750
21270 / NCT05128825: A Phase 2 study to evaluate efficacy and safety of Azenosertib (ZN-c3) in high grade serous ovarian cancer as 2+line
Learn more: https://clinicaltrials.gov/study/NCT05128825
25114 MAESTRA 1 / NCT07023627: Phase 2 study of INCB123667 as 2-5L treatment in patients with platinum resistant high grade serous epithelial OC, FP, or PPC with Cyclin E1 overexpression.
Learn more: https://clinicaltrials.gov/study/NCT07023627
PERITONEAL
21270 / NCT05128825: A Phase 2 study to evaluate efficacy and safety of Azenosertib (ZN-c3) in primary peritoneal cancer as 2+ line
Learn more: https://clinicaltrials.gov/study/NCT05128825
24112 CATALINA-2 / NCT06690775: Phase 2 study of TORL-1-23 in advanced platinum resistant epithelial primary peritoneal cancers expressing claudin 6 in 2-4 line setting. Tumor must be CLDN6+ positive
Learn more: https://clinicaltrials.gov/study/NCT06690775
25114 MAESTRA 1 / NCT07023627: Phase 2 study of INCB123667 as 2-5L treatment in patients with platinum resistant high grade serous epithelial OC, FP, or PPC with Cyclin E1 overexpression.
Learn more: https://clinicaltrials.gov/study/NCT07023627